Dr. Volker Gerdts, VIDO Director

USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

Posted on

The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization (VIDO) at the University of Saskatchewan (USask).

“We are excited to start clinical trials,” said VIDO Director Dr. Volker Gerdts. “Our team has worked hard to advance the development of this vaccine to help combat the COVID-19 pandemic.” 

The trial was designed as a combined Phase 1/Phase 2 study. Phase 1 will vaccinate 108 healthy volunteers in a placebo-controlled study at the Canadian Center for Vaccinology (CCfV) in Halifax. Two doses will be administered to each volunteer 28 days apart….


Read More Impact Stories

Posted on
McGill-developed device offers 100 per cent accuracy in as little as 10 minutes, and can be configured to detect a [...]
Posted on
This content is available in French only.
Posted on
The University of Toronto and Moderna, Inc. known for its mRNA-based COVID-19 vaccine plan to work together to develop new [...]